ARTEMIS BIO-SUPPORT B.V.

Their core work

ARTEMIS Bio-Support is a Dutch biomedical SME based in Delft that provides specialist biological support services, most likely including animal models, biological testing, and preclinical research capabilities — their website (artemiswildlifehealth.eu) signals a core grounding in wildlife and veterinary biology. In H2020, they have participated in projects spanning from cross-border disease outbreak surveillance to blood-brain-barrier drug delivery research, suggesting they serve as a versatile biological services partner for research consortia. Their value to project partners lies in applied biological expertise that bridges veterinary science, translational medicine, and preclinical testing. They are a niche SME operating at the intersection of animal biology and human health research.

What they specialise in

How they've shifted over time

In their first H2020 project (COMPARE, 2014–2019) ARTEMIS contributed to a One Health disease surveillance platform, where their wildlife and veterinary biology background was directly relevant to monitoring zoonotic and foodborne outbreaks. By 2019 their focus had shifted sharply toward CNS neuroscience, joining IM2PACT to work on blood-brain-barrier permeability and iPSC-based drug delivery models — a move into translational pharmacology that is quite distant from outbreak surveillance. The trajectory suggests the organisation is actively repositioning, either by diversifying its service offer into preclinical CNS research or by following a specific client or consortium opportunity into a new domain.

ARTEMIS appears to be moving from broad veterinary/One Health monitoring toward specialist preclinical CNS and drug delivery research, which could make them a useful biological partner for neurological disease consortia seeking animal model or translational testing expertise.

How they like to work

ARTEMIS has participated exclusively as a consortium partner — never as a coordinator — across both of their H2020 projects, suggesting they prefer to contribute specialist services rather than lead and manage large consortia. Despite only two projects, they have accumulated 55 unique consortium partners across 15 countries, which implies they joined large, multi-partner RIAs where they played a defined technical role rather than a generalist one. Working with them likely means engaging a focused SME that delivers a specific biological capability within a broader project structure.

ARTEMIS has worked with 55 distinct consortium partners across 15 countries, a broad network for an SME with only two projects, reflecting their involvement in large pan-European RIA consortia. No geographic concentration is evident beyond their Dutch base.

What sets them apart

ARTEMIS is an unusual SME that combines a commercial foundation in wildlife and veterinary health with active participation in cutting-edge biomedical research — from disease outbreak detection to BBB drug delivery modelling. This cross-domain biological expertise is rare among private companies their size and makes them potentially attractive to consortia that need an applied biology partner with both field-level animal expertise and in-vitro preclinical capabilities. Their small size means they are typically available for focused, well-defined technical roles within larger research collaborations.

Highlights from their portfolio

• COMPARE
  A high-profile One Health RIA with a large consortium, COMPARE positioned ARTEMIS at the frontier of cross-species disease surveillance, the most directly aligned with their wildlife health commercial identity.
• IM2PACT
  Represents a striking thematic pivot into CNS neuroscience and iPSC modelling, signalling ARTEMIS's ambition to enter the brain drug delivery research space — far from their veterinary origins.